Eli Lilly's gene-editing therapy, VERVE-102, demonstrated a 62% reduction in LDL cholesterol levels during a Phase 1 clinical trial, with no reported safety issues. This promising treatment, acquired in a $1 billion deal with Verve Therapeutics, aims to provide a one-time solution for lowering cholesterol and potentially preventing heart disease.
Eli Lilly's Phase 1 trial results for VERVE-102, a gene-editing therapy acquired for $1 billion, show a 62% reduction in LDL cholesterol with no serious safety issues. This positions VERVE-102 as a promising candidate for transforming cholesterol management and potentially reducing heart disease risk, highlighting a significant investment opportunity in gene-editing therapies with favorable early safety profiles.